摘要：Animal experiments are generally conducted at higher dose levels than anticipated human dose levels in order to elicit otherwise subtle changes in reproduction or developmental effects with relatively few animals. Based on animal data, regulatory strategy generally has been to postulate a no-observed-effect level (NOEL) for toxic effects and to divide this by a safety factor, usually 100, to establish acceptable levels for humans. Various authors have discussed the shortcomings of using NOEL and have suggested the use of an estimable effect level determined from a dose-response curve fitted to bioassay data, e.g., the dose at which 1% of the animals are adversely affected, and employing some form of conservative low dose extrapolation to control risks at lower doses. In this paper, 10 sets of bioassay data on fetal mortality or anomalies were used to compare the estimated upper limits of risk estimated at the NOEL/100 and the lower 95% confidence limit estimate of the dose producing adverse effects in 1% of the embryonic implants or fetuses divided by 100 (LED01/100). The latter quantity is expected to result in a risk (proportion affected) of less than 10(-4) (1 in 10,000). The estimated upper limits of risk associated with the NOEL/100 were from 2 x 10(-4) to 6 x 10(-4) for the 10 data sets investigated. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (590K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References . 243 244 245 246
Loading...
